Lessons from cost-effectiveness research for United States public health policy

被引:83
作者
Grosse, Scott D. [1 ]
Teutsch, Steven M.
Haddix, Anne C.
机构
[1] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabilities, Coordinating Ctr Hlth Promot, Atlanta, GA 30333 USA
[2] Merck & Co Inc, Outcomes Res & Management, West Point, PA 19486 USA
[3] Ctr Dis Control & Prevent, Off Strategy & Innovat, Atlanta, GA 30333 USA
关键词
economic evaluation; cost-benefit analysis; regulation; health policy; immunization; newborn screening;
D O I
10.1146/annurev.publhealth.28.021406.144046
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
The application of cost-effectiveness analysis to health care has been the subject of previous reviews. We address the use of economic evaluation methods in public health, including case studies of population-level policies, e.g., environmental regulations, injury prevention, tobacco control, folic acid fortification, and blood product safety, and the public health promotion of clinical preventive services, e.g., newborn screening, cancer screening, and childhood immunizations. We review the methods used in cost-effectiveness analysis, the implications for cost-effectiveness findings, and the extent to which economic studies have influenced policy and program decisions. We discuss reasons for the relatively limited impact to date of economic evaluation in public health. Finally, we address the vexing question of how to decide which interventions are cost effective and worthy of funding. Policy makers have funded certain interventions with rather high cost-effectiveness ratios, notably nucleic acid testing for blood product safety Cost-effectiveness estimates are a decision aid, not a decision rule.
引用
收藏
页码:365 / 391
页数:27
相关论文
共 146 条
[1]   Evidence-based public health policy and practice: Promises and limits [J].
Anderson, LM ;
Brownson, RC ;
Fullilove, MT ;
Teutsch, SM ;
Novick, LF ;
Fielding, J ;
Land, GH .
AMERICAN JOURNAL OF PREVENTIVE MEDICINE, 2005, 28 (05) :226-230
[2]  
[Anonymous], 2006, Valuing Health for Regulatory Cost-Effectiveness Analysis
[3]  
[Anonymous], 2005, EC MOD COL CANC SCRE
[4]   Safety of the blood supply in the United States: Opportunities and controversies [J].
AuBuchon, JP ;
Birkmeyer, JD ;
Busch, MP .
ANNALS OF INTERNAL MEDICINE, 1997, 127 (10) :904-909
[5]  
Baily MA, 2005, J LAW MED ETHICS, V33, P46
[6]  
Bala MV, 2002, AM J MANAG CARE, V8, P211
[7]   Implications of spillover effects within the family for medical cost-effectiveness analysis [J].
Basu, A ;
Meltzer, D .
JOURNAL OF HEALTH ECONOMICS, 2005, 24 (04) :751-773
[8]  
Berger M L, 1999, Jt Comm J Qual Improv, V25, P455
[9]  
Berger ML, 2005, MED CARE, V43, P49
[10]  
Beutels P, 2004, PEDIATRICS, V114, P1375, DOI 10.1542/peds.2004-1283